gip glp 1 receptor agonist Targeting GLP-1, & GCG in Obesity and Type 2 Diabetes Research Science Behind GLP 1 GIP

This guide examines peer-reviewed research on EVOO and GLP-1 secretion, hydroxytyrosol and insulin sensitivity, oleocanthal and inflammation, and why these olive-specific compounds are distinct from other dietary polyphenols

Compare semaglutide, tirzepatide, and retatrutide head to head

Using a global dataset and propensity matching, they found significantly lower mortality rates, major cardiovascular events (MACEs), and adverse kidney outcomes (MAKEs) among GLP-1 RA users compared to non-users

Dr Reddys launches oral semaglutide biosimilar tablets, offering broader access to diabetes and weight-loss therapies in India.

Some sub-analyses of large clinical trials suggest that GLP-1RA and sodium-glucose cotransporter 2 inhibitor combination therapy may provide more significant reductions in heart failure hospitalization and renal composite events than each alone

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for glycaemic control in patients with type 2 diabetes, have demonstrated significant cardiometabolic benefits